Stay updated with breaking news from Nasdaq Acad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.04), Briefing.com reports. ACADIA Pharmaceuticals had a negative return on equity of 16.24% and a negative net margin of 8.44%. The company […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.04), Briefing.com reports. ACADIA Pharmaceuticals had a negative return on equity of 38.84% and a negative net margin of 23.55%. The business had […]
ClariVest Asset Management LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 33,304 shares of the biopharmaceutical company’s stock, valued at approximately $694,000. A number of other hedge funds have also […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Analysts at Leerink Partnrs lifted their FY2023 earnings estimates for shares of ACADIA Pharmaceuticals in a research note issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($0.33) for the year, up from their […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research note published on Friday, Benzinga reports. The firm currently has a $42.00 price target on the biopharmaceutical company’s stock. ACAD has been the topic of several other research reports. Stifel Nicolaus raised their price target on shares […]